ClinicalTrials.gov
ClinicalTrials.gov Menu

HLA Sensitization in Severely Burned Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02537821
Recruitment Status : Recruiting
First Posted : September 2, 2015
Last Update Posted : November 21, 2017
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
Primary goal of this study is the analysis of HLA (Human leucocyte antigen) formation in severly burned patients. Potential HLA triggers in the treatment of severely burned patients are blood products, assist devices or temporary allogeneic skin. Besides that, inflammatory markers, such as WBC (white blood cell count), CRP (C-reactive protein), PCT (Procalcitonin) and two novel biomarkers (PSP (pancreatic stone protein), ST2) are to be investigated in severely burned patients.

Condition or disease
Severely Burned Patients

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: HLA Sensitization in Severely Burned Patients
Study Start Date : June 2015
Estimated Primary Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns




Primary Outcome Measures :
  1. HLA antibody formation (HLA Sensitization) (Unit: PRA in %) [ Time Frame: Change from Baseline (admission) in HLA antibody count at 2 weeks, 4 weeks, 3 months and 6 months ]
    The degree of sensitization is reported as the percentage of CDC (Complement dependent Cytotoxicity) Panel Reactive Antibody (PRA). Unit is %.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Severely burned patients
Criteria

Inclusion Criteria:

  • severely burned patients in need for hospitalization

Exclusion Criteria:

  • hematologic diseases
  • Cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02537821


Contacts
Contact: Jan Plock, M.D. 0041 (0)44 2551111 jan.plock@usz.ch

Locations
Switzerland
University Hospital Zurich Recruiting
Zurich, Switzerland, 8091
Contact: Jan Plock, M.D.         
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Jan Plock, M.D. Raemistrasse 100, 8091

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02537821     History of Changes
Other Study ID Numbers: PKSF-01-2014
First Posted: September 2, 2015    Key Record Dates
Last Update Posted: November 21, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Burns
Wounds and Injuries